Trial Profile
Effects of variability of mean erythrocyte corpuscular volume on progression free survival in patients with advanced gastrointestinal stromal tumour receiving imatinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Dec 2015
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 16 Dec 2015 New trial record